Etpa
I was speaking about Direct Phase I data. We do not know the baseline of each patients. We have no idea what their expected survival was meant to be. Big Pharma, in my opinion, will not take those survival lines seriously without removing all potential biases. They need to see everything under the trunk. And the fact remains that majority of the patients did not advance beyond 2 weeks. And the other vast majority did not advance beyond 4 weeks. It is going to be very hard, without strong supporting data, to prove the survival (even if it is long) has anything to do with patients who failed a study. Now, if you're asking me if I think the vaccine slows down death, my opinion based on DCVax-L data, it might be doing that. I do not know if it is. BUT I also know it will be SO tough to prove it's DCVax-Direct, and there are other drugs that have much more provable data.
But on the subject of the CUA data, it's impossible too. We do not which patients were psPD or which were rPD. Both exist within a pool of rapid progression data. That said it's getting to a point now that even the Indeterminate Arm is living longer than most psPD do. If it continues on that track, that Indeterminate arm will look good in comparison to psPD too.
RK
Market Data 
Markets 
